文献速递胸部肿瘤

ROS1阳性非小细胞肺癌患者血浆的分子分析

Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC.
PubMed 文献 · J Thorac Oncol · 2019-01-18

该研究比较血浆与组织基因分型检测ROS1融合的谱系和敏感性,血浆检出7种融合伴侣,CD74-ROS1占多数(血浆63%,组织50%),7例双方法检测患者融合类型100%一致,克唑替尼耐药后血浆ROS1融合检出敏感性为50%。

要点

  • 血浆基因分型可捕获组织中所见的ROS1融合谱系。
  • CD74-ROS1融合在血浆(63%)和组织(50%)中均占主导。
  • 克唑替尼耐药后血浆ROS1融合检出敏感性为50%。

核心结论

  • 血浆基因分型可捕获组织中所见的ROS1融合谱系,是检测ROS1靶向治疗耐药驱动突变的有前景方法。

研究设计与样本

  • 研究查询Guardant Health血浆数据集和一家机构组织数据库,比较血浆与组织结果。
  • 使用Guardant360 NGS assay检测克唑替尼复发ROS1阳性NSCLC患者血浆中的潜在耐药遗传介质。

主要发现

  • 血浆中检出7种不同融合伴侣,其中6种也在组织数据集中出现。
  • CD74-ROS1融合在血浆中占35/56(63%),在组织中占26/52(50%)。
  • 7例同时用两种方法基因分型的患者,组织和血浆检测的特定ROS1融合100%一致。
  • ROS1靶向治疗复发时血浆检测ROS1融合的敏感性为50%。
  • 18份克唑替尼后血浆标本中6份(33%)携带ROS1激酶域突变,其中5份为ROS1 G2032R。

临床怎么用

  • 血浆基因分型是检测ROS1靶向治疗耐药驱动突变的有前景方法。

局限性

  • 与其他NSCLC分子亚群相比,血浆中检测ROS1遗传改变的经验有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Circulating tumor DNA analysis is an emerging genotyping strategy that can identify tumor-specific genetic alterations in plasma including mutations and rearrangements. Detection of ROS1 fusions in plasma requires genotyping approaches that cover multiple breakpoints and target a variety of fusion partners. Compared to other molecular subsets of NSCLC, experience with detecting ROS1 genetic alterations in plasma is limited. METHODS: To describe the spectrum of ROS1 fusions in NSCLC and determine sensitivity for detecting ROS1 fusions in plasma, we queried the Guardant Health plasma dataset and an institutional tissue database and compared plasma findings to tissue results. In addition, we used the Guardant360 NGS assay to detect potential genetic mediators of resistance in plasma from patients with ROS1-positive NSCLC who were relapsing on crizotinib. RESULTS: We detected seven distinct fusion partners in plasma, most of which (n = 6 of 7) were also represented in the tissue dataset. Fusions pairing CD74 with ROS1 predominated in both cohorts (plasma: n = 35 of 56, 63%; tissue: n = 26 of 52, 50%). There was 100% concordance between the specific tissue- and plasma-detected ROS1 fusion for seven patients genotyped with both methods. Sensitivity for detecting ROS1 fusions in plasma at relapse on ROS1-directed therapy was 50%. Six (33%) of 18 post-crizotinib plasma specimens harbored ROS1 kinase domain mutations, five of which were ROS1 G2032R. Two (11%) post-crizotinib plasma specimens had genetic alterations (n = 1 each BRAF V600E and PIK3CA E545K) potentially associated with ROS1-independent signaling. CONCLUSIONS: Plasma genotyping captures the spectrum of ROS1 fusions observed in tissue. Plasma genotyping is a promising approach to detecting mutations that drive resistance to ROS1-directed therapies.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Dagogo-Jack I, Rooney M, Nagy RJ, et al. Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC. J Thorac Oncol. 2019. PMID: 30664990. doi:10.1016/j.jtho.2019.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。